The future of psychedelic drug design in mental health treatment

Research is exploring how redesigned compounds could retain therapeutic potential while reducing hallucinations and other unwanted effects

Psychedelic substances have gradually moved from being seen as fringe or experimental drugs to becoming an important area of research in mental health treatment. Substances such as ketamine, psilocybin, lysergic acid diethylamide (LSD) and other psychedelic compounds are currently being investigated for conditions such as depression, post-traumatic stress disorder (PTSD) and anxiety disorders. Although the results from research so far have been promising, these treatments are still largely investigational for psychiatric use in the UK. There are also important questions remaining about their safety, effectiveness, accessibility and how they should be used in clinical settings.

To read the full blog: Click here